| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-664SS | |||
| Azide and BSA Free | NBP2-81007 | |||
NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surface and cytoplasm." alt="ICAM‑1/CD54 was detected in live unfixed C32 human melanoma cell line using Mouse Anti-Human ICAM‑1/CD54 Monoclonal Antibody (Catalog # BBA3) at 5 µg/mL for 1 hour at 2° - 8° C. Cells were then fixed with 4% formaldehyde followed by incubation with the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surface and cytoplasm." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | BBA20 | |||
HAF018). A specific band was detected for CD31/PECAM-1 at approximately 130 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human CD31/PECAM-1 Monoclonal Antibody (Catalog # BBA7) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for CD31/PECAM-1 at approximately 130 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB3567P-100 | |||
| Carrier Free | FAB3567P-025 | |||
| Carrier Free | FAB3567F-100 | |||
| Carrier Free | FAB3567F-025 | |||
| Carrier Free | FAB3567A-100 | |||
| Carrier Free | FAB3567A-025 | |||
| Carrier Free | FAB3567N-100 | |||
| Carrier Free | FAB3567N-025 | |||
| Carrier Free | FAB3567C-100 | |||
| Carrier Free | FAB3567C-025 | |||
210-TA, filled histogram) or rested (open histogram) and stained with Mouse anti-human E-selectin/CD62E (BBA16) followed by Goat anti-Mouse APC-conjugated secondary antibody (F0101B). Gates were set based on isotype control (MAB002, data not shown). Staining was performed using our Staining Membrane-associated Proteins protocol. " alt="Human umbilical cord endothelial cells (HUVECs) were cultured for 6 hours in the presence of 25 ng/mL of rhTNF-alpha (210-TA, filled histogram) or rested (open histogram) and stained with Mouse anti-human E-selectin/CD62E (BBA16) followed by Goat anti-Mouse APC-conjugated secondary antibody (F0101B). Gates were set based on isotype control (MAB002, data not shown). Staining was performed using our Staining Membrane-associated Proteins protocol. " class="big_thumb" />
NL007) and counter-stained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.This antibody is not suitable for labeling formalin-fixed, paraffin-embedded tissue." alt="VCAM-1/CD106 was detected in immersion fixed HUVEC human umbilical vein endothelial cells using Human VCAM-1/CD106 Monoclonal Antibody (Catalog # BBA5) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the Northern-Lights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (yellow; Catalog # NL007) and counter-stained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips.This antibody is not suitable for labeling formalin-fixed, paraffin-embedded tissue." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-71663SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47491SS | |||
| Azide and BSA Free | NBP2-81005 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56585SS | |||
| Azide and BSA Free | NBP2-33232 | |||
| Azide and BSA Free | NBP2-33232-1mg | |||
NL007) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips." alt="E-Selectin (CD62E)/P-Selectin (CD62P) was detected in immersion fixed HUVEC human umbilical vein endothelial cells stimulated with TNF-alpha (Catalog # 210-TA-010) using Mouse Anti-Human E-Selectin (CD62E)/P-Selectin (CD62P) Monoclonal Antibody (Catalog # BBA1) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the Northern-Lights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (yellow; Catalog # NL007) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB6169P | |||
| Carrier Free | FAB6169A | |||
| Carrier Free | FAB6169F | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-69753SS | |||
210-TA, filled histogram) or rested (open histogram) and stained with Mouse anti-human E-selectin/CD62E (BBA26) followed by Goat anti-Mouse APC-conjugated secondary antibody (F0101B). Gates were set based on isotype control (MAB002, data not shown). Staining was performed using our Staining Membrane-associated Proteins protocol. " alt="Human umbilical cord endothelial cells (HUVECs) were cultured for 6 hours in the presence of 25 ng/mL of rhTNF-alpha (210-TA, filled histogram) or rested (open histogram) and stained with Mouse anti-human E-selectin/CD62E (BBA26) followed by Goat anti-Mouse APC-conjugated secondary antibody (F0101B). Gates were set based on isotype control (MAB002, data not shown). Staining was performed using our Staining Membrane-associated Proteins protocol. " class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-34685-0.1mg | |||
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib reduced TNBC cell migration & targeted p-STAT3/VEGF-A signaling.(A) Chemical structure of regorafenib. (B,C), Transwell assay (B) & wound-healing assay (C) were performed in TNBC cell lines after regorafenib treatment for 24 h. *p < 0.05, **p < 0.01. (D) dose-dependent effects of regorafenib on p-STAT3 & VEGF-A proteins were analyzed by western blot. (E) Dose-dependent effects of regorafenib on VEGF-A mRNA were analyzed by qPCR. TNBC cells were exposed to the indicated doses for 24 hours. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-310202415382436.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - SC-78, a derivative of regorafenib, exhibited more potent anti-migratory effects than regorafenib.(A) Chemical structure of SC-78. (B) The protein levels of p-VEGFR2, VEGFR2, p-PDGFR, & PDGFR in EAhy926 treated with various doses of regorafenib or SC-78 were determined by western blot. (C,D), The effect of SC-78 on migration of human TNBC cells was analyzed by Transwell migration assay (C) & wound-healing assay (D). *p < 0.05, **p < 0.01. (E) Human TNBC cells were treated with SC-78 dose dependently for 24 h, & the cell lysates were subjected to western blot assay. (F) MDA-MB-231 cells were transfected with vector control or VEGF-A overexpression plasmid (left), STAT3 overexpression plasmid (middle), scramble or SHP-1 siRNA (right), respectively. After 48 h transfection, cells were treated with SC-78 (2.5 μM) for 24 h & subjected to western blot assay or cells analyzed by Transwell migration assay. *p < 0.05, **p < 0.01. (G) SHP-1 activity assay was performed in MDA-MB-231 & MDA-MB-468 cells treated with SC-78 dose dependently. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-310202415535199.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Anti-tumor activity of regorafenib & SC-78 in a murine TNBC metastasis model.(A) Nude mice were subcutaneously injected with MDA-MB-468 cells (2 × 106). Mice were treated with vehicle, bevacizumab (125 μg/100 μl, twice a week, IP), regorafenib, or SC-78 (10 mg/kg, everyday, oral) for 43 days (n = 6), & the tumor size (left, bottom) was measured. In vivo protein levels were analyzed (Middle, top). Middle, bottom, the in vivo SHP-1 activity. Right, Representative images of IHC staining (100 × ). *p < 0.05, **p < 0.01. (B) Luciferase-expressing MDA-MB-231 (1 × 106) cells were injected orthotopically into the mammary fat pad of the mice. After two weeks, mice received regorafenib & SC-78, or vehicle orally at 10 mg/kg/every day (n = 5). Tumor growth was monitored by IVIS imaging system at the indicated times. Left, top, visualized by IVIS analysis. Left, bottom, quantification analysis from the IVIS total flux. Right, Representative images of IHC staining (100×). *p < 0.05, **p < 0.01. (C) In vivo bioluminescence images of nude mice injected i.v. with MDA-MB-231/Luc2 cells (1 × 106). After bioluminescence was observed, mice received vehicle or SC-78 orally at 10 mg/kg/every day. left, visualized by IVIS analysis. Right, Kaplan–Meier plot showing animal survival after treatment with vehicle or SC-78 (n = 8). The survival endpoint was set at 64 days after drug administration. (D) Schematic displays the drug mechanism of regorafenib & SC-78 on VEGF-A autocrine & paracrine inhibition & cell migration. SC-78 suppressed cancer metastasis dominantly through SHP-1 dependent-STAT3 dephosphorylation. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-310202415523928.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-31020241555228.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Notch-1 is identified as an intermediate molecule in the miR-1956-VEGF axis. (A) Notch-1 is a target gene for miR-1956. The sequence of miR-1956, the potential binding site at the 3' UTR of Notch-1 mRNA, & the nucleotides mutated in the Notch-1-3' UTR mutant are shown. HEK293 cells were transiently cotransfected with miR-1956 mimic or NC using luciferase reporter vectors. The luciferase activity was normalized to the activity of Renilla luciferase. Data are shown as mean ± SD from three independent experiments. *, significantly different from NC; **, p < 0.01. After transfection with 50 nmol/L of miR-1956 mimic for 3 days, the mRNA level of Notch-1 was determined using qRT-PCR (B), & the protein expression of Notch-1 was measured using western blotting (C). For B, data are shown as mean ± SD from three independent experiments. *, significantly different from control; **, p < 0.01. For C, representative images of two independent experiments are shown. Data are shown as mean ± SD. *, significantly different from control; **, p < 0.01. ADMSCs were transfected with 2.5 μg Notch-1 plasmid & 50 nmol/L miR-1956 mimic or 100 nmol/L miR-1956 inhibitor for 3 days, the intracellular expression of Notch-1 (D) & VEGF (E) was detected by western blotting. For D & E, representative images of four independent experiments are shown. Data are shown as mean ± SD. *, significantly different from the control group transfected with control plasmid & NC mimic or inhibitor; *, p < 0.01; **, p < 0.01. #, significantly different from the group transfected with Notch-1 plasmid & NC mimic or inhibitor; #, p < 0.05. One-way ANOVA followed by Tukey's post-test was performed (A-E). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31938051), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-310202415535177.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - SHP-1 is negatively associated with p-STAT3/VEGF-A signaling & metastasis in TNBC cells & clinical samples.(A) Protein expression pattern of SHP-1, p-STAT3, & VEGF-A in nine TNBC cell lines were analyzed by western blot. (B) The migration abilities of nine TNBC cell lines were analyzed by Transwell assay. DAPI stains the nuclei. BT-20 cells were used as a normalization control. (C) The correlation (linear regression model) of VEGF-A (top), p-STAT3 (middle), & SHP-1 (bottom) & migration ability in nine TNBC cell lines. (D) TNBC cells from representative two patients with SHP-1, p-STAT3, & VEGF-A staining. (200×) (E) Kaplan-Meier graph was prepared to compare DMFS (left) & DFS (right) in patients with high VEGF-A (H score > 160) or low VEGF-A (H score < = 160) levels for the indicated time of follow up. Chi-square test indicated a significant difference between VEGF-A high (N = 21) & low (N = 76) patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-3102024155374.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-31020241682159.jpg)
![Analysis of a FFPE tissue section of human liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-664_mouse-monoclonal-vegf-antibody-vg1-immunohistochemistry-paraffin-1211202510571.jpg)
![Analysis of a FFPE tissue section of mouse liver using 1:200 dilution of VEGF antibody [VG1]. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-664_mouse-monoclonal-vegf-antibody-vg1-immunohistochemistry-paraffin-12112025105832.jpg)
HAF018). A specific band was detected for ICAM‑1/CD54 at approximately 85 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Western Blot Buffer Group 1." class="big_thumb" />
MAB002) followed by anti-Mouse IgG PE-conjugated Secondary Antibody (
NL007) and counterstained with DAPI (blue). View our protocol for 
NL007) and counterstained with DAPI (blue). Specific staining was localized to cell membrane. Staining was performed using our protocol for Fluorescent ICC Staining of Non-adherent Cells." class="big_thumb" />
VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # 
NL007) and counterstained with DAPI (blue). View our protocol for 
CTS013). Tissue was stained with the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # 
ADP1) was serially diluted and captured by Mouse Anti-Human E‑Selectin/CD62E Monoclonal Antibody (Catalog # BBA16) coated on a Clear Polystyrene Microplate (Catalog # 
NL007) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane. View our protocol for ![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0009.jpg "Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.")
![Simple Western: CD31/PECAM-1 Antibody [NBP1-71663] - Image shows a specific band for CD31/PECAM 1 in 0.5 mg/mL of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Simple-Western-NBP1-71663-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - HUVEC cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with CD31/PECAM-1 Antibody at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0011.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody [NBP1-71663] - CD31/PECAM-1 Antibody was tested in WeHi cells with Dylight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Flow-Cytometry-NBP1-71663-img0005.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NBP1-71663] - Detection of CD31 in HUVEC cell lysates.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Western-Blot-NBP1-71663-img0008.jpg)
![Western Blot: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Using VCAM1 mouse mAb against (1) HUVEC and (2) EC cell lysate.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Western-Blot-NBP1-47491-img0006.jpg "Western Blot: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Using VCAM1 mouse mAb against (1) HUVEC and (2) EC cell lysate.")
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - (A) human lung cancer and (B) colon cancer using VCAM1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0004.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Human placenta tissues using VCAM1 mouse mAb.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0005.jpg)
![Immunohistochemistry: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Breast carcinoma, cytoplasmic staining. IHC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-NBP1-47491-img0007.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - FFPE section of human lung cancer. Image at 20X magnification. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0009.jpg)
![Simple Western: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Lane view shows a specific band for CD106/VCAM1 in 0.5 mg/mL of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Simple-Western-NBP1-47491-img0008.jpg)
![Immunocytochemistry/ Immunofluorescence: VCAM-1/CD106 Antibody (6G9) - BSA Free [NBP1-47491] - Enhanced expression of endothelial SENP1 & GATA2 correlates w/ graft arteriosclerosis (GA) progression.Similarly sized human coronary arteries w/ GA from chronically rejecting heart allografts or w/out disease from non-transplanted hearts collected & evaluated by histological analysis. (a,b) Dramatically increased expression of endothelial SENP1 detected in the diseased vessel wall. Endothelial SENP1 expression is demonstrated by immunofluorescence analysis of coronary artery cross-sections that stained for SENP1 & the endothelial marker PECAM-1 w/ DAPI labelling of the nuclei. Representative images are shown in (a) w/ quantification data in (b). Bar represents 50 μm. (c) Induction of endothelial adhesion molecules resulted in a similar augmented pattern as endothelial SENP1. Representative images of immunofluorescence staining for VCAM-1 or P-selectin & PECAM-1 in coronary arteries w/ DAPI counterstaining are shown. Bar represents 50 μm. (d,e) Expression of endothelial GATA2 elevated w/ the progression of aggravated rejection. Representative images of the immunofluorescence staining of coronary arteries for GATA2 & PECAM-1 together w/ DAPI nuclear staining are shown in (d) w/ quantification data in (e). Negative SENP1 & GATA2 staining in the isotype or blocking peptide controls are also shown in (a) & (d). Bar represents 50 μm. Data presented in (b,e) are the mean±s.e.m. from five separate clinical specimens per group as indicated. *P<0.05, **P<0.01 & ***P<0.0001; one-way ANOVA followed by Bonferroni test. GA, graft arteriosclerosis; PECAM, platelet/endothelial cell adhesion molecule; SENP, sentrin-specific protease; VCAM, vascular cell adhesion molecule. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15426), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47491_mouse-monoclonal-vcam-1-cd106-antibody-6g9-310202416161834.jpg)
![Immunocytochemistry/ Immunofluorescence: VCAM-1/CD106 Antibody (6G9) - BSA Free [NBP1-47491] - Loss of endothelial SENP1 inhibits EC activation.(a) Grafts from WT or SENP1-ecKO mice were harvested 3 days post-transplantation. The induction of endothelial adhesion molecules was demonstrated by immunofluorescence staining of ICAM-1, VCAM-1, or P-selectin & PECAM-1 with DAPI labelling of the nuclei. Bar represents 50 μm. (b–e) Attenuated induction of adhesion molecules in SENP1-ecKO MAECs. Flow cytometry analysis of ICAM-1, VCAM-1 & P-selectin in MAECs isolated from WT or SENP1-ecKO mice after TNF or IL-1 beta treatment. Representative histograms are shown in (b) with the quantification of mean intensity in (c–e). (f–h) Overexpression of the catalytically inactive form of SENP1 (SENP1-Mut) inhibits the induction of adhesion molecules in HUVECs. HUVECs were infected by Ad-SENP1-Mut or vector control (Ad-LacZ) for 24 h, treated with pro-inflammatory cytokines & analysed by flow cytometry in the same way as MAECs. Representative histograms of ICAM-1 & VCAM-1 are shown in (f) with the quantification of mean intensity in (g,h). Data are presented as the mean±s.e.m. from at least three independent experiments. *P<0.05 & **P<0.01; two-way ANOVA followed by Bonferroni post-test. MAEC, mouse aortic endothelial cell. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15426), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47491_mouse-monoclonal-vcam-1-cd106-antibody-6g9-31020241616185.jpg)
![Western Blot: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Detection in TEM8 transfected cell lysate using this antibody.](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Western-Blot-NB100-56585-img0018.jpg "Western Blot: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Detection in TEM8 transfected cell lysate using this antibody.")
![Immunohistochemistry-Paraffin: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Detection of TEM8/ANTXR1 in human liver cancer section using 5 ug/ml concentration of TEM8 antibody. Uniform weak staining was observed in the cancerous cells, while the blood vessels depicted the expected intense positivity for TEM8.](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Immunohistochemistry-Paraffin-NB100-56585-img0016.jpg)
![Western Blot: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Analysis of human heart lysates (35ug per lane, RIPA buffer) using TEM8 antibody (NB100-56585) at 0.3ug/ml. Band observed at 65kDa. (Expected MW of 62.8kDa according to NP_115584.1).](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Western-Blot-NB100-56585-img0017.jpg)
![Immunohistochemistry-Paraffin: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Human colon stained with TEM8 antibody at 2.5 ug/ml concentration using DAB chromogen detection method (10X magnification)](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Immunohistochemistry-Paraffin-NB100-56585-img0015.jpg)
![Western Blot: Tie-2 Antibody [NBP1-69753] - Total protein from human Huvec cells and mouse stomach tissue was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TIE2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Tie-2-Antibody-Western-Blot-NBP1-69753-img0006.jpg "Western Blot: Tie-2 Antibody [NBP1-69753] - Total protein from human Huvec cells and mouse stomach tissue was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TIE2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: Tie-2 Antibody [NBP1-69753] - Analysis of a FFPE tissue section of mouse stomach using 1:200 dilution of Tie-2 antibody (NBP1-69753). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/Tie-2-Antibody-Immunohistochemistry-Paraffin-NBP1-69753-img0007.jpg)
![Western Blot: Tie-2 Antibody [NBP1-69753] - Detection of TIE2 in Huvec cell lysate](http://images.novusbio.com/fullsize/Tie-2-Antibody-Western-Blot-NBP1-69753-img0003.jpg)
![Simple Western: Tie-2 Antibody [NBP1-69753] - Simple Western lane view shows a specific band for Tie-2 in 0.5 mg/ml of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Tie-2-Antibody-Simple-Western-NBP1-69753-img0005.jpg)
210-TA) using Mouse Anti-Human E-Selectin/CD62E Monoclonal Antibody (Catalog # BBA26) at 5 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # ![Western Blot: Moesin Antibody (MSN/491) [NBP2-32875] - Western Blot Analysis of human PC3 cell lysate using Moesin Antibody (MSN/491).](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Western-Blot-NBP2-32875-img0014.jpg "Western Blot: Moesin Antibody (MSN/491) [NBP2-32875] - Western Blot Analysis of human PC3 cell lysate using Moesin Antibody (MSN/491).")
![Immunocytochemistry/Immunofluorescence: Moesin Antibody (MSN/491) [NBP2-32875] - Immunofluorescence Analysis of PFA-fixed HeLa cells labeling Moesin with Moesin Antibody (MSN/491) followed by Goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Red Dot (Red)](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Immunocytochemistry-Immunofluorescence-NBP2-32875-img0013.jpg)
![Immunohistochemistry-Paraffin: Moesin Antibody (MSN/491) [NBP2-32875] - Fomalin-paraffin Rat colon stained with Moesin MAb (MSN/491)](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Immunohistochemistry-Paraffin-NBP2-32875-img0010.jpg)
![Flow Cytometry: Moesin Antibody (MSN/491) [NBP2-32875] - Flow Cytometric Analysis of K562 cells using Moesin Antibody (MSN/491) followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Flow-Cytometry-NBP2-32875-img0012.jpg)
![Western Blot: Moesin Antibody (MSN/491) [NBP2-32875] - Analysis using the Azide and BSA Free version of NBP2-32875. Detection of Moesin in human HT29 Cells.](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Western-Blot-NBP2-32875-img0006.jpg)
![Immunohistochemistry-Paraffin: Moesin Antibody (MSN/491) [NBP2-32875] - Formalin-paraffin human placenta stained with Moesin MAb (MSN/491)](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Immunohistochemistry-Paraffin-NBP2-32875-img0007.jpg)
![Immunohistochemistry-Paraffin: Moesin Antibody (MSN/491) [NBP2-32875] - Formalin-paraffin human Melanoma stained with Moesin Mab (MSN/491)](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Immunohistochemistry-Paraffin-NBP2-32875-img0008.jpg)
![Immunohistochemistry-Paraffin: Moesin Antibody (MSN/491) [NBP2-32875] - Formalin-paraffin Rat Lung stained with Moesin MAb (MSN/491)](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Immunohistochemistry-Paraffin-NBP2-32875-img0009.jpg)
![Simple Western: Moesin Antibody (MSN/491) [NBP2-32875] - Simple Western lane view shows a specific band for Moesin in 0.1 mg/ml of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Simple-Western-NBP2-32875-img0003.jpg)
![Simple Western: Moesin Antibody (MSN/491) [NBP2-32875] - Electropherogram image of the corresponding Simple western lane view. Moesin antibody was used at 1 ug/ml dilution on HUVEC lysate(s) respectively.](http://images.novusbio.com/fullsize/Moesin-Antibody-MSN-491-Simple-Western-NBP2-32875-img0004.jpg)
